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Brain-derived neurotrophic factor (BDNF) is a key mediator of the activity-dependent processes in the
brain that have a major impact on neuronal development and plasticity. Impaired control of neuronal
activity-induced BDNF expression mediates the pathogenesis of various neurological and psychiatric
disorders. Different environmental stimuli, such as the use of pharmacological compounds, physical and
learning exercises or stress exposure, lead to activation of speciﬁc neuronal networks. These processes
entail tight temporal and spatial transcriptional control of numerous BDNF splice variants through
epigenetic mechanisms. The present review highlights recent ﬁndings on the dynamic and long-term
epigenetic programming of BDNF gene expression by the DNA methylation, histone-modifying and
microRNA machineries. The review also summarizes the current knowledge on the activity-dependent
BDNF mRNA trafﬁcking critical for rapid local regulation of BDNF levels and synaptic plasticity. Cur-
rent data open novel directions for discovery of new promising therapeutic targets for treatment of
neuropsychiatric disorders.
This article is part of the Special Issue entitled ‘BDNF Regulation of Synaptic Structure, Function,
and Plasticity’.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Brain-derived neurotrophic factor (BDNF) is a central player in
neuronal plasticity and the development of different neurological
and psychiatric disorders. Impaired regulation of BDNF expression
has been implicated in mood and anxiety disorders, early-life
adverse experience and aging, cognitive and neurodegenerative
diseases (Autry and Monteggia, 2012; Boulle et al., 2012; Erickson
et al., 2012; Frielingsdorf et al., 2012; Mahan and Ressler, 2012;
Roth and Sweatt, 2010). BDNF is involved in neurogenesis, neuronal
survival and differentiation and long-term potentiation (Hall et al.,
2000; Jones et al., 1994; Schwartz et al., 1997). Studies in BDNF-null
mice or mice with the Val66Met polymorphism have demonstrated
that BDNF is a key regulator of plasticity, dendritic arborization,
learning and memory and synaptic morphogenesis (Abidin et al.,
2008, 2006; Soliman et al., 2010).
Rodent and human BDNF genes have multiple untranslated 50-
exons; every single 50-exon is normally spliced to one coding exon
with two different 30-UTRs (untranslated region), resulting in
dozens of possible BDNF transcripts variants, each of which en-
codes an identical BDNF protein (Aid et al., 2007; Liu et al., 2005;Y-NC-ND license.Pruunsild et al., 2007). On rare occasions human BDNF transcripts
might consist of multiple (up to 3) 50-exons and one coding exon
(Pruunsild et al., 2007), however the molecular mechanisms of
these exceptional alternative splicing events are not studied.
Importantly, all 50-exons and both 30-UTRs are under the control of
their own regulatory elements, providing the cells with an excep-
tional molecular device that can be controlled in an activity-
dependent, stimulus-speciﬁc temporal and spatial manner (Aid
et al., 2007; An et al., 2008; Chiaruttini et al., 2008; Hong et al.,
2008; Pruunsild et al., 2007, 2011).
The responsiveness of BDNF to multiple cellular signaling
pathways underlines its physiological function in the activity-
regulated neuronal network. Moreover, several environmental
stimuli, as will be discussed in this review, lead to long-term
epigenetic control of BDNF expression. The variations in BDNF
levels between cells/individuals/disease states may result not only
from genetic polymorphism but also from altered epigenetic pro-
gramming. Indeed, the genome is not a one-dimensional linear
DNA sequence that deﬁnes a genotype. A DNA helix is folded into
several layers of highly organized chromatin structure to form a
chromosome. Knowing the sequence of a protein-coding region of a
gene is insufﬁcient for understanding its functioning because
chromatin structure dramatically affects gene expression. The
actual genome (or epigenome) is an active cooperation of 1) ge-
notype, 2) chromatin modiﬁcations (DNA methylation and histone
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as microRNAs; transposable elements), driven by the dynamic
environment. Here I will review the main epigenetic modiﬁcations
that may lead to reprogramming of BDNF expression within
differentiated non-dividing neurons or may be potentially inheri-
ted by dividing brain cells without changes in the BDNF gene
sequence per se.
The main concept of the present review is that dynamic varia-
tion in BDNF expression and the subsequent changes in brain
functioning and neuronal plasticity are under tight environmental
control. Speciﬁc focus is paid to those epigenetic changes that drive
the activity-dependent alterations in BDNF transcripts levels,
temporal or spatial, critical for neuronal plasticity, development of
diseases and their treatments. Particularly, this review highlights
the recent work on the epigenetic regulation of the BDNF gene that
occurs in adult animals or humans, although some key ﬁndings on
BDNF reprogramming during critical periods of postnatal devel-
opment and in neuronal cell cultures are also discussed to provide
better insight into the molecular mechanisms of the epigenetic
control of BDNF expression.
2. Impact of DNA methylation on BDNF expression
DNA methylation is a fundamental epigenetic mechanism for
gene silencing throughout lifespans (Bird, 2002; Reamon-Buettner
and Borlak, 2007). DNA methyltransferases (DNMT) catalyze the
transfer of a methyl group from a donor S-adenosylmethionine to a
cytosine at position C5, resulting in a new nucleotide 5-mC, 5-
methylcytosine, generally in the context of CpG dinucleotides
(Fig. 1) (Lister and Ecker, 2009). The vast majority of CpGs in
mammalian genomes are methylated and contribute to the for-
mation of condensed heterochromatin (Bird, 2002). In contrast,
hypomethylated CpG sites are located mostly in the CpG islands
(CG-rich DNA regions) in close vicinity to genes promoters (Bird
et al., 1985; Weber et al., 2007). In dividing cells, maintainingFig. 1. DNA methylation at gene promoter region. The transfer of a CH3-group from the me
catalyzed by DNA methyltransferases, DNMT. Low DNA methylation level is correlated with
histone acetylases, HAT, and RNA polymerase II, Rpol II, to promoter region (left). Increase
MeCP2, and a chromatin silencing complex that contains histone deacetylases, HDAC, andDNMT1 recognizes the hemi-methylated CpG site, which is
generated during DNA replication, and controls the correct incor-
poration of a methyl group into newly synthesized DNA strands,
copying the methylation pattern from mother to daughter cells
(Bird, 2007). In addition to the maintaining DNMT1, the methyl-
transferases DNMT3a and DNMT3b are the key enzymes processing
de novo DNA methylation independent of DNA replication. De novo
DNA methylation together with DNA demethylation are predomi-
nantly thought to be implicated in neuronal plasticity (Levenson
et al., 2006; Nelson et al., 2008).
2.1. BDNF and methylated DNA-binding proteins: case of MeCP2
How does the DNA methylation state at promoter regions affect
the level of gene expression?Methylated CpG sites are identiﬁed by
speciﬁc methyl-CpG-binding proteins (Nan et al., 1997; Ng et al.,
2000; Prokhortchouk et al., 2001; Skene et al., 2010; Wade et al.,
1999) that modify chromatin structure through the recruitment
of transcriptional repressor complexes (Fig. 1) (Yoon et al., 2003;
Zhang et al., 1999). Mutations in methyl-CpG-binding protein 2
(MeCP2) are associated with Rett syndrome (RTT), a severe pro-
gressive neurological disorder characterized by autistic behavior,
mental retardation and motor dysfunction (Amir et al., 1999). Pa-
tients with RTT begin to present the characteristics of the disease
only after 6e18 months of age (Hagberg et al., 1983). A similar
phenotype is observed in the mouse models of RTT, MeCP2-mutant
or null mice, which grow normally until 5e6 postnatal weeks of age
(Chen et al., 2001; Guy et al., 2001). Thus, the development of RTT
has been attributed to the lack of MeCP2 function in adult neurons
(Luikenhuis et al., 2004; Skene et al., 2010) and glial cells (Ballas
et al., 2009; Diaz de Leon-Guerrero et al., 2011; Maezawa et al.,
2009).
Accumulating evidence suggests that aberrant regulation of
activity-dependent BDNF expression largely contributes to the
neuronal phenotype observed in RTT: abnormalities in dendriticthyl donor S-adenosylmethionine to the cytosine in the CpG dinucleotide sequence is
the increased gene transcription level through the binding of transcription factors, TF,
d amount of methylated CpG sites recruits methylated DNA-binding proteins, such as
histone methyltransferases, HMT, resulting in the repressed gene transcription (right).
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maturation (Zhou et al., 2006), altered excitatory synaptic plasticity
(Moretti and Zoghbi, 2006) and increased inhibition (Dani et al.,
2005). Interesting, although MeCP2 has been suggested to act as
a global chromatin regulator (Skene et al., 2010), BDNF has been
found to be selectively regulated byMeCP2 in response to neuronal
activity (Chen et al., 2003; Martinowich et al., 2003; Zhou et al.,
2006). More speciﬁcally, an environmental stimulus, such as the
membrane depolarization of cultured neurons, induced a calcium
inﬂux and consequent MeCP2 phosphorylation (Tao et al., 1998),
which in turn decreased the binding of MeCP2 to methylated CpGs
at the activity-dependent BDNF promoter IV (Aid et al., 2007), thus
facilitating BDNF transcription (Chen et al., 2003; Martinowich
et al., 2003). It has been recently shown that the loss of activity-
dependent phosphorylation of MeCP2 not only increased BDNF
exon IV expression but also improved synaptogenesis, long-term
potentiation (LTP) and spatial memory in mice (Li et al., 2011).
Taken together, the mechanism of epigenetic regulation of the
BDNF gene by the repressor MeCP2 suggests enhanced BDNF
expression in the absence of MeCP2. However, MeCP2 deﬁciency in
RTT, both in humans and mice, results in the down-regulation of
BDNF brain level (Chang et al., 2006). Moreover, the morphology of
MeCP2-deﬁcient neurons has been shown to be rescued by BDNF
overexpression (Larimore et al., 2009). The complex multiple-
promoter structure of the BDNF gene itself would suggest a po-
tential mechanism for such discrepancy. Indeed, several recent
studies noted the importance of neuronal activity-dependent
transcription from the BDNF promoter I, one of the targets of a
neuronal gene repressor REST (RE1-silencing transcription factor,
also known as neuron-restrictive silencing factor, NRSF)
(Abuhatzira et al., 2007; Bruce et al., 2004; Hara et al., 2009; Tian
et al., 2009). Together, these studies support the idea that in
healthy mature neurons, the REST gene is essentially repressed by
MeCP2 and that transcription from both BDNF promoters I and IV is
actively but differentially regulated (Pruunsild et al., 2011). In
contrast, in the absence of MeCP2 in Rett syndrome, REST is over-
expressed, thus inhibiting the induction of BDNF I transcription in
response to neuronal activity (Abuhatzira et al., 2007; Hara et al.,
2009). Although a number of additional factors may be impli-
cated in neuropathology of MeCP2 deﬁciency, it would be of great
interest to determine whether deregulation of activity-dependent
transcription from the BDNF promoter I plays a key role in the
aberrant neuronal phenotypes observed in the patients with Rett
syndrome.
2.2. BDNF DNA methylation and neurological disorders
Neuronal activity induces dynamic DNA methylation changes in
the BDNF gene region. Increased DNA methylation at the promoter
area normally promotes a state of transcriptional repression
(Robertson and Wolffe, 2000; Suzuki and Bird, 2008) through
repressive chromatin remodeling governedmainly bymethyl-CpG-
binding proteins (Bird, 2002; Klose and Bird, 2006). Environmental
stimuli may alter the levels of DNA methylation and consequently
gene expression, generating long-lasting cellular memories. Inter-
estingly, dynamic demethylation speciﬁcally at the CREB-binding
site in the avian BDNF promoter region and elevated binding of
phospho-CREB to that promoter in the hypothalamus have been
associated with thermal conditioning during the critical period for
sensory development in chicks (Yossifoff et al., 2008). Associative
learning during fear conditioning promoted dynamic DNA
methylation at the BDNF locus in the hippocampus of adult rats
(Lubin et al., 2008). Importantly, differential activation of hippo-
campal BDNF exons I and IV via decreased DNA methylation has
been suggested to be a key mechanism in discriminating betweenassociative (fear conditioning) versus non-associative (context
learning) long-term memories (Lubin et al., 2008).
Emerging evidence suggests that elevated BDNF exon IV DNA
methylation is a mechanism for BDNF down-regulation in adverse
environmental circumstances. Traumatic stress experience, such as
continuous psychosocial stress, induced hypermethylation of the
BDNF IV region and reduced the BDNF expression in the dorsal CA1
area of the hippocampus in PTSD-like rats (Roth et al., 2011).
Increased DNA methylation at the BDNF promoter IV in the hip-
pocampus of adult mice has been correlated with depression-like
behavior (Onishchenko et al., 2008). Moreover, prolonged light
deprivation in adult rats induced repressive methylation at the
BDNF promoter IV both in the visual cortex and hippocampus
(Karpova et al., 2010), suggesting a molecular mechanism that may
predispose light-deprived animals to the depression-like behavior
and stress (Gonzalez and Aston-Jones, 2008). Furthermore, recent
ﬁndings on post-mortem brain samples from suicide completers
has revealed signiﬁcant hypermethylation at speciﬁc CpG sites in
the BDNF IV region and a concomitant decrease in BDNFmessenger
RNA in theWernicke area comparedwith samples fromnonsuicidal
subjects (Keller et al., 2010). Changes in the genome-wide level of
DNA methylation have not been detected in suicide individuals,
implicating an epigenetic gene-speciﬁc pattern in the Wernicke
area in the pathology of suicide behavior (Keller et al., 2010).
Following these studies, it would be of interest to also investigate
the potential correlation between DNA methylation levels at the
BDNF promoter I in the brain and the development of neurological
diseases. Recently, Fuchikami et al. (2011) demonstrated that the
DNAmethylation proﬁle of a CpG island at the BDNF promoter I, but
not IV, in human blood may serve as a valuable diagnostic tool for
major depressive disorder. This study suggests an important pros-
pect for identifying new epigenetic biomarkers of neuropsychiatric
disorders to improve the classiﬁcation system, which is currently
based on clinical symptoms.
2.3. DNA methylation is reversible
Recent research highlights that the abnormal DNA methylation
found in numerous disorders of the nervous system may be
potentially responsive to environmental changes, such as nutrition,
physical activity or pharmacological treatments. Although DNA
methylation patterns at speciﬁc gene loci may remain stable over
long periods and serve as a basis for the development of the dis-
eases, DNA methylation is a dynamic and reversible process. DNA
demethylationmay be induced by inhibition ofmaintainingDNMT1
during mitotic DNA replication (Szyf, 2007). DNMT inhibitors, the
nucleoside analogues 5-aza-cytidine and 5-aza-2-deoxycytidine,
mimicked the behavioral effects of the antidepressant imipramine
in adult mice and rats through a dose-dependent inhibition of
BDNF DNA methylation in the hippocampus (Sales et al., 2011).
Moreover, the DNMT inhibitor zebularine has been shown to
induce exon-speciﬁc BDNF expression through DNA demethylation
mechanisms in the rat hippocampus (Lubin et al., 2008). In this
study, Lubin et al. (2008) implicated hippocampal NMDA receptor
activation in the epigenetic enhancement of BDNF transcription
and contextual fear memory because NMDA receptor blockade by
MK801 prevented decreased DNA methylation levels around the
BDNF promoter IV.
Although the DNMT inhibitors potentially implicate the dividing
glial cells and neurogenesis in reduction of DNA methylation
levels under some environmental conditions; however, rapid
demethylation of speciﬁc genes in the mammalian brain in
response to environmental signals is most likely to involve active
replication-independent mechanisms. Evidence for existence of a
speciﬁc DNA demethylase that may directly remove the methyl
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et al., 1999) and current knowledge suggests a key role of the
base excision repair machinery in active DNA demethylation (Zhu,
2009). Tet methylcytosine dioxygenases (TET) convert 5-mC to 5-
hmC, 5-hydroxymethylcytosine, that can be further deaminated
by AID/APOBEC, activation-induced cytidine deaminase/apolipo-
protein B mRNA editing enzyme catalytic polypeptide, to produce a
DNA mismatch that is then repaired by the base excision repair
machinery (Zhu, 2009). TET1 (Tahiliani et al., 2009) has been
recently shown to induce DNA demethylation speciﬁcally at the
neuronal activity-dependent BDNF and FGF1B promoters regions
through oxidation-deamination mechanism (Guo et al., 2011).
These studies highlight a potential sensitivity of BDNF expression to
altered environmental conditions through its dependence on
changes in oxygen levels.
A neural activity-dependent member of the DNA repair ma-
chinery, growth arrest DNA-damage-inducible beta (GADD45b),
has been implicated in the activity-induced site-speciﬁc removal of
methyl groups from the BDNF locus, neurogenesis and neural
plasticity (Gavin et al., 2012;Ma et al., 2009). Induction of GADD45b
by LY379268, a brain-permeable mGlu2/3 (metabotropic glutamate
receptor) agonist, reduced DNAmethylation levels at the promoters
of genes for reelin, BDNF and glutamate decarboxylase 67 and
reversed defects in social interaction in adult mice pretreated with
the methyl group donor (Matrisciano et al., 2011). These ﬁndings
implicated epigenetic mechanisms in the efﬁcacy of the mGlu2/3
agonists as antipsychotic agents (Conn et al., 2009; Gewirtz and
Marek, 2000).
Age- or nutrition-associated decreases in nicotinamide adenine
dinucleotide (NAD) levels have been suggested to provide a critical
link between the decelerated cellular metabolism and decreased
BDNF signaling that might contribute to cognitive impairment
(Chang et al., 2010). Interestingly, in cortical neurons with low NAD
levels, the amount of DNA methylation has been elevated at the
BDNF promoter IV, leading to BDNF silencing, and, in contrast,
increased NAD concentration restored the BDNF level (Chang et al.,
2010). A critical role in the NAD-dependent regulation of BDNF
expression through chromatin remodeling has been attributed to
the binding of the DNA methylationesensitive factor CTCF associ-
ated with cohesin (Chang et al., 2010), mutations in which are
thought to trigger severe mental retardation (Dorsett, 2009).
Neuronal activity, stimulated by voluntary exercise, has been
associated with induced hypomethylation at the BDNF IV region
and increased BDNF expression via the MeCP2-dependent pathway
in adult rats (Gomez-Pinilla et al., 2011), underlining the potential
molecular mechanism for the positive effects of exercise on mental
health.
3. Histone modiﬁcations at BDNF promoters
Methylated DNA-binding proteins represent a direct link be-
tween DNA methylation and histone modiﬁcations. For instance,
MeCP2 recruits a co-repressor protein complex that contains
histone-modifying enzymes such as histone deacetylases (HDAC)
(Fig. 1). This complex leads to transcriptional silencing through the
formation of a “closed” local chromatin structure (Nan et al., 1997).
Nuclear DNA in eukaryotes is wrapped around the core nucleo-
somal complex consisting of a histone octamer (Kouzarides, 2007).
Histones are subjects to posttranslational covalent modiﬁcations,
the majority of which occur at the N-terminal unfolded tails of the
four core histones (H2A, H2B, H3 and H4). Distinct histone modi-
ﬁcations inﬂuence the accessibility of the transcription factors to
DNA by regulating the association of the histone tail with the ATP-
dependent chromatin remodeling complex (Kouzarides, 2007).
Moreover, the particular combinations of histone modiﬁcationsaround a gene form a “histone code” that speciﬁes the time- and
cell type-dependent pattern of gene expression (Jenuwein and
Allis, 2001), resulting in a “loss-of-function” or “gain-of-function”
gene phenotype without alterations in the DNA sequence (Szyf,
2007). Generally, histone modiﬁcations are permissive or repres-
sive for gene transcription (Fig. 2). For instance, acetylation of ly-
sines (or “K” in the single amino-acid code) is associated with the
activation of gene transcription, whereas lysine methylationmostly
serves as a mark of gene silencing with the exception of modiﬁ-
cations of a few speciﬁc lysines (Li et al., 2007).
3.1. BDNF activation through histone acetylation
Histone acetyl transferases (HATs) in a complex with their
cofactor (acetyl-coenzyme A) catalyze the lysine acetylation that
neutralizes the basic charge of tight DNA-histone interactions. In
contrast, histone deacetylases (HDACs) mediate the removal of the
acetylation mark, resulting in the formation of DNA that is less
accessible to transcription factors (Kouzarides, 2007; Lee and
Workman, 2007).
Drug abuse has been consistently shown to affect neuronal ac-
tivity through epigenetic mechanisms. Kumar et al. revealed
histone-speciﬁc acetylation in response to acute or chronic cocaine
administration. Acute cocaine increased histone H4 acetylation at
the cFos and FosB promoters, whereas chronic cocaine induced the
sustained acetylation of histone H3 at the BDNF and Cdk5 pro-
moters in the rat striatum (Kumar et al., 2005). This result was
similar to the effect of chronic electroconvulsive seizures in the
hippocampus (Tsankova et al., 2004). Activation of a permissive
chromatin state and phospho-CREB protein binding to the BDNF
promoter IV in the rat prefrontal cortex has been implicated in
cocaine-induced neuronal plasticity (Sadri-Vakili et al., 2010). In
contrast, cocaine abstinence promoted histone H3 acetylation and
the consequent increase in BDNF I transcription in the ventral
tegmental area (Schmidt et al., 2012). Epigenetic activation of the
BDNF I transcription level in the ventromedial prefrontal cortex
(vmPFC) through acetylation of histone H3 has been associated
with the successful extinction of aversive memories of morphine
withdrawal (Wang et al., 2012). The authors showed that extinction
training could be potentiated by an intra-vmPFC infusion of the
HDAC inhibitor trichostatin A (TSA) and by increased CREB protein
binding to the acetylated BDNF promoter (Wang et al., 2012).
Emerging evidence suggests that epigenetic reprogramming of
BDNF by chronic cocaine intake may not only alter neuronal and
behavioral phenotype in the cocaine-addicted male rats but also
could be transmitted to their next generation (Vassoler et al., 2013).
In this study, chronic cocaine induced histone H3 acetylation at the
BDNF promoters I, IV and VI in the sperm of addicted rats. Inter-
estingly, their male, but not female, offspring showed a cocaine-
resistant phenotype associated with the increased BDNF tran-
scription level and histone H3 acetylation speciﬁcally at the BDNF
promoter IV in the prefrontal cortex (Vassoler et al., 2013).
Although the mechanisms of conservation of this histone mark has
not been investigated and may involve additional epigenetic
changes in DNA/histone methylation (Santos et al., 2005) at the
BDNF locus, this study highlights a possibility for the trans-
generational maintenance of the BDNF epigenetic state.
Proper histone acetylation levels have been shown to affect LTP
and long-term memories (Alarcon et al., 2004). For instance,
increased histone H4 acetylation around BDNF promoters I and IV
in the prefrontal cortex contributed to improved extinction of
conditioned fear in mice (Bredy et al., 2007). Moreover, the HDAC
inhibitor valproic acid (VPA) enhanced not only the extinction of
cued fear memory but also its acquisition and reconsolidation
(Bredy and Barad, 2008). Interestingly, a single exposure to
Fig. 2. Histone modiﬁcations at BDNF promoters. Different environmental stimuli affect the DNA methylation pattern and lead to the formation of the repressive (more condensed)
or active (more open) chromatin structure, resulting in the decreased or increased gene transcription, respectively. Histone acetylation (open triangle) at lysine, K, is an epigenetic
imprint of transcriptionally active chromatin, whereas histone methylation (closed blue box) is mostly associated with repressed chromatin. Phosphorylation (patterned circle) at
serine, S, threonine, T, or tyrosine, Y, is generally linked to gene activation.
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lation of histones H3 and H4 at the activity-dependent BDNF pro-
moters I and IV and heightened the hippocampal levels of BDNF
transcription, thus strengthening the subsequent consolidation of
fear memories (Takei et al., 2011). This study suggests a molecular
mechanism for the elevated long-lasting traumatic fear memories
in patients with PTSD.
Recently, several studies have reported anHDAC inhibition effect
of some antidepressants as well as mood- and cognition-enhancing
effects of HDAC inhibitors. In particular, hyperacetylation at the
BDNF promoters IV and VI (nomenclature adapted to (Aid et al.,
2007)) and selective down-regulation of HDAC5 by the chronic tri-
cyclic antidepressant imipramine restored the hippocampal BDNF
expression, which had been decreased by chronic social defeat
stress in mice (Tsankova et al., 2006). Accordingly, the administra-
tion of the selective serotonin reuptake inhibitor (SSRI) ﬂuoxetine to
adult mice promoted histone H3 acetylation at the promoter BDNF
IV and reversed depression-like behavior, which had been induced
by perinatal exposure to an environmental contaminant, methyl-
mercury (Onishchenko et al., 2008). Interestingly, neither imipra-
mine nor ﬂuoxetine altered the repressive histone methylation
status induced by stressful conditions (Onishchenko et al., 2008;
Tsankova et al., 2006). Importantly, both ﬂuoxetine and the HDAC
inhibitor TSAhave been shown to reactivate visual cortical plasticity
in adult rats, promoting a transient increase in BDNF expression
through histone hyperacetylation at its promoters (Maya
Vetencourt et al., 2011). This study also highlighted a critical role
for the 5-HT(1A) receptor and BDNF signaling pathway in estab-
lishing a plastic state in the visual cortex because local infusion of
the 5-HT(1A) receptor antagonist WAY-100635 into the visual
cortex prevented permissive histone remodeling at the BDNF pro-
moters and reactivation of visual cortical plasticity (Maya
Vetencourt et al., 2011).An epigenetic strategy for treating impaired synaptic plasticity
and cognitive declines during aging has been suggested by Zeng
et al. (2011). Using hippocampal slices from young and aged rats,
the authors showed a robust decline in LTP and dendritic spine
number and a signiﬁcant decrease in BDNF expression and
signaling in aged animals. The reduction in BDNF coincided with
hypoacetylated states of histone H3 and/or H4 at essentially all
BDNF promoters. However, short-term treatment of hippocampal
slices with TSA or sodium butyrate not only promoted an increase
in H3/H4 acetylation levels but also restored the LTP and spine
density to the levels observed in young animals (Zeng et al., 2011). It
would be of great interest to investigate whether this enhanced
synaptic plasticity induced by acute HDAC inhibitors has a long-
lasting effect on cognitive improvement.
3.2. Histone methylation effects on BDNF expression
Histone methyltransferases (HMTs) and demethylases (HDMTs)
catalyze histone methylation and demethylation, respectively, at
lysine or arginine residues. Activation of gene transcription is
associated with increased methylation of histone H3 at lysine 4
(H3K4) and at lysine 36 (H3K36); however, the majority of other
methylation events at histone residues H3K9, H3K14, H3K27, and
H4K20 at gene promoters normally mediate transcriptional inac-
tivation (Kouzarides, 2007). For instance, incorporation of the
methyl moiety from a methyl-donor, S-adenosylmethionine, to
histone residues H3K27 and H3K4 is catalyzed by different HMT
complexes, the Polycomb (PcG) silencing complex and the Tri-
thorax (TrxG) activating complex, respectively (Papp and Muller,
2006). The tri-methylated H3K27me3 variant has been shown to
mediate transcriptional repression by inhibiting the deposition of
activating histone acetylation marks that are important to form an
“open” chromatin state (Schuettengruber et al., 2007).
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through repressive histone H3 methylation at the BDNF promoters
in rodent brains (Karpova et al., 2010; Onishchenko et al., 2008;
Tsankova et al., 2006). In contrast, a positive environmental inﬂu-
ence, such as environmental enrichment, has been shown to pro-
duce opposite changes. Indeed, 3e4weeks of mouse exposure to an
enriched environment signiﬁcantly increased hippocampal BDNF
expression through complex histone remodeling at its promoters
(Kuzumaki et al., 2011). Activating histone marks (methylated
H3K4) at promoters III and VI were elevated, whereas repressive
methylation of H3K9 and H3K27 were markedly decreased at
promoters III and/or IV (Kuzumaki et al., 2011). Complex regulation
of BDNF and other plasticity-related genes levels by histone
methylation has been critically involved in fear memory formation
(Gupta et al., 2010), implicating the G9a/GLP histone methyl-
transferase complex in the regulation of neuronal connectivity
during the consolidation of long-term fear memories (Gupta-
Agarwal et al., 2012). Interestingly, viral overexpression of the
HMT G9a in the critical brain reward region, the nucleus accum-
bens, after chronic cocaine administration repressed local BDNF
signaling and rendered mice less vulnerable to subsequent stress
(Covington et al., 2011), see also (Maze et al., 2010). In contrast,
acute nicotine exposure signiﬁcantly down-regulated the G9a/GLP
complex in the mouse cortex and, subsequently, reduced the
H3K9me2 histone mark at the BDNF promoters, thus activating
BDNF expression (Chase and Sharma, 2012). Gaining more insight
into the mechanisms of action of the HMT complex G9a/GLP couldFig. 3. Post-transcriptional regulation of BDNF transcripts. Nucleus: Structure of the rodent
VIII (open boxes) and one coding exon IX (gray box). ATG, start codon that indicates initiatio
tail. Cytoplasm: Different BDNF transcripts are translated into protein or targeted to the
dendritic targeting may be regulated by the inhibitory or permissive signals (located in exons
complex). Particular microRNAs binding to the BDNF 30-UTR may result in the repression of
or in the BDNF transcripts degradation.identify new potential therapeutic targets for treatments of mood
and addictive disorders.
4. Post-transcriptional regulation of BDNF mRNA levels and
trafﬁcking
Rapid synapse-speciﬁc responses to environmental stimuli have
a critical role in the ﬁne tuning of neuronal plasticity. Activity-
dependent mRNA targeting and protein synthesis in dendrites
suggest a mechanism for rapid local regulation of the activity of
plasticity-related molecules such as BDNF (Bramham and Wells,
2007; Tongiorgi et al., 1997). The multiple-promoter structure of
BDNF and BDNF splice variants with different 50 and 30-UTRs (Fig. 3)
serve as excellent and complex cellular tools not only for the
temporal neuronal response to distinct stimulating cues but also for
the differential spatial distribution of BDNF transcripts (Aid et al.,
2007; An et al., 2008; Chiaruttini et al., 2008, 2009; Pruunsild
et al., 2007).
4.1. 50-Exons mediated BDNF mRNA trafﬁcking
Studies in neuronal culture showed that BDNF transcripts tar-
geting to dendrites might be promoted by a constitutively active
element in the protein-coding region, while multiple 50-UTRs with
either inhibitory or permissive signals for dendritic targeting
controlled the transcript-selective trafﬁcking (Chiaruttini et al.,
2009). Indeed, BDNF splice variants with exons I and IV wereBDNF gene (adapted from Aid et al., 2007) consists of multiple 50 untranslated exons Ie
n of transcription. 30-UTR of BDNF transcripts is composed of either short or long polyA
distal cellular compartments (distal dendrites) for the local translation later on. The
), short or long 30-UTRs and multiple regulatory microRNAs (bound to the Ago2-protein
the local translation into BDNF protein and, thus, in dendritic targeting of BDNF mRNAs
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scripts containing exon II or IV were found in more distal cellular
compartments (Chiaruttini et al., 2008, 2009). Moreover, dendritic
targeting through a constitutively active element in the coding
region was mediated by an RNA-binding protein Translin, and its
interaction with BDNF mRNA was blocked by the G196A (or
Val66Met) mutation (Chiaruttini et al., 2009). Thus, in addition to
the impaired BDNF protein vesicular release for the Val66Met
polymorphism (Chen et al., 2005), this mutation may also
compromise mRNA trafﬁcking to distal dendrites. These ﬁndings
implicate improper BDNF sorting in the learning and memory im-
pairments and susceptibility to mood disorders of Met allele car-
riers (Chen et al., 2006; Krishnan et al., 2007; Soliman et al., 2010).
4.2. BDNF dendritic targeting by its 30-UTR
The activity-dependent trafﬁcking of speciﬁc BDNF transcripts is
further regulated by the inducible signals located in the 30-UTR.
BDNF mRNAs with the short 30-UTR have been shown to be mostly
concentrated and translated in the cell soma to maintain the basal
level of the BDNF protein. In contrast, the long 30-UTR-containing
transcripts were targeted to dendrites, where their translation may
be robustly up-regulated upon neuronal activation (An et al., 2008;
Lau et al., 2010). Importantly, targeting to dendrites appears to be
associated with the cis-acting translation suppressor located in the
long BDNF 30-UTR (Lau et al., 2010). Furthermore, different types of
environmental stimuli, such as KCl-induced depolarization in rat
hippocampal neurons, have also been shown to activate the den-
dritic trafﬁcking of the transcripts with the short 30-UTR (Oe and
Yoneda, 2010). A novel critical link between BDNF and energy
balance has been determined by Liao et al. (2012). The researchers
showed that the local dendritic translation of BDNF mRNAwith the
long 30-UTR could be stimulated by leptin and insulin in rodent
hypothalamic neurons. This study implicated dendritic localization
and local BDNF protein synthesis in the control of feeding behavior
and susceptibility to obesity (Liao et al., 2012).
4.3. MicroRNA control of BDNF transcripts
Local dendritic translation and mRNA stability are primarily
thought to be regulated bymicroRNAs (Fig. 3). The BDNF 30-UTR has
been predicted to contain up to 20 binding sites for microRNAs
from 13 families (Wu et al., 2010). Key components of themicroRNA
maturation machinery offer a tool for modulating BDNF expression.
In the nucleus, the long hairpin-containing transcript for microRNA
is processed by RNase III Drosha into double-stranded pre-micro-
RNA that is exported to the cytoplasm (Heo and Kim, 2009). In the
cytoplasm, RNase III Dicer cleaves and removes the hairpin loop
and processes the pre-microRNA into 21- to 23-nucleotide du-
plexes, generating mature microRNAs. Then, mature microRNAs in
a complex with the Argonaute protein bind to the targeted mRNAs
in a sequence-speciﬁc manner to cleave them or suppress their
translation (Bartel, 2009). A conditional knockout of the Dicer1
gene in an adult mouse forebrain produced a massive loss of the
brain-speciﬁc microRNAs, resulting in increased BDNF translation,
spine morphogenesis and memory enhancement (Konopka et al.,
2010). Moreover, huntingtin, a key protein implicated in the path-
ogenesis of Huntington’s disease, has been shown to be associated
with the transporting neuronal granules that contain BDNF mRNA
and the Argonaute2 complex (Ma et al., 2010). Although more
in vivo data are required, this ﬁnding suggests a role of huntingtin
and/or the microRNA processing complex-mediated transport of
BDNF transcripts in the development of Huntington’s disease.
The effect of particular microRNAs in the post-transcriptional
control of BDNF expression is now beginning to be elucidated(Caputo et al., 2011; Lee et al., 2012; Miura et al., 2012), and an
inspiring strategy for treatments of speciﬁc neurological disorders
has already been suggested. Indeed, the repressive function of a
microRNA, miR-206, on BDNF expression through binding its 30-
UTR (Miura et al., 2012) has been up-regulated in Alzheimer dis-
ease, both in a transgenic Tg2576 mouse model and in humans (Lee
et al., 2012). However, intra-ventricle injection or intra-nasal
administration of an antagomir (AM206, an inhibitor of miR-206)
not only increased the BDNF levels in the brains of the Tg2576
mice but also prevented dendritic spine degeneration and memory
impairments (Lee et al., 2012). This study suggests the possibility of
using non-invasive approaches to treat such devastating neurode-
generative disorders as Alzheimer disease.
5. Conclusions
The BDNF gene is regulated by neural activity in a temporal and
spatial manner. The cellular-compartment, cell-type and tissue-
speciﬁc epigenetic pattern of the BDNF gene critically differs from
that of its genetic polymorphisms. The studies exploring the gain-
of-function (e.g., systemic/local overexpression) or loss-of-
function (e.g., full/conditional knockout) methodologies do not
provide complete information about the role of BDNF in active
processes in the brain, such as neuronal differentiation or survival,
migration or spine development (Hong et al., 2008). Acquiring
better knowledge on the epigenetic regulation of such a complex-
structured gene as BDNF would promote the development of
more safe and effective treatments for neurological and psychiatric
disorders.
The epigenetic state of the BDNF gene might not necessarily
change its expression levels at a given time point butmay underline
a predisposition to mood, addictive or neurodegenerative disor-
ders, as well as non-responsiveness to treatment strategies, when
triggered by aversive environmental conditions. The epigenome is
dynamic and speciﬁc environmental manipulations, such as phar-
macological or psychological (behavioral in animals) therapies,
could direct the epigenetic reprogramming of a disease state to-
ward recovery. It’s important to warn, however, that current
epigenetic pharmacological treatments affect the functioning of the
whole epigenome. Although the use of the epigenetic drugs such as
DNMT, HDAC or microRNA inhibitors is growing, the selectivity of
these drugs in restoring the epigenetic pattern of only the partic-
ular genes implicated in the pathogenesis of disease is largely un-
studied at this point. To prevent potential harmful (cytotoxic or
carcinogenic) effects of these drugs on cell/tissue functioning
throughout the body, thorough research should be performed to
discover therapeutically beneﬁcial agents with limited side effects.
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